FDA Drug recall D-0877-2018
Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morga…
- FDA Drug
- Class III
- terminated
- Published 2018-06-20
On 2018-06-20 the FDA classified a Class III recall of Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morga… by Mylan Pharmaceuticals, citing superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0877-2018 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2018-06-07 |
| Published | 2018-06-20 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Mylan Pharmaceuticals |
| Distribution | US |
Product
Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01
Reason
Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.
Identifiers
| code_info | Lot #: 3087136, Exp 5/20 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0877-2018%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.